Clinical Overview

Infantile hemangiomas are benign vascular tumors affecting 4-5% of children by age 5, making them most common tumor in infants. Resulting from rapid proliferation of endothelial cells, these lesions typically appear in first weeks to months of life. While most involute spontaneously, some cause significant morbidity including airway compromise, visual obstruction, disfigurement, or bleeding. Early recognition and appropriate intervention minimize complications and optimize cosmetic outcomes. Propranolol has revolutionized treatment, providing 60-90% size reduction in most cases.

Epidemiology

Infantile hemangiomas affect 4-5% of infants, with higher incidence in premature infants (12%), low birthweight infants (22%), and following placental abnormalities. Female predominance of 3-5:1 consistently reported. Lesions typically appear within first 2 weeks of life, though 10-15% appear later. Multiple hemangiomas occur in 25%. Associated PHACES syndrome (Posterior fossa abnormalities, Hemangioma, Arterial anomalies, Cardiac defects, Eye abnormalities, Sternal cleft) occurs in 7-10% of large facial hemangiomas.

Pathophysiology

Infantile hemangiomas develop from dysregulated proliferation of endothelial cells with abnormal vasculogenesis. Characteristic proliferative phase (0-12 months, average 6 months), plateau phase, and involution phase (1-7 years, average 5 years). Propranolol's mechanism involves beta-2 adrenergic receptor inhibition in endothelial cells, reducing angiogenesis and promoting apoptosis. VEGF, bFGF, and other growth factors promote endothelial cell proliferation.

Clinical Presentation

Hemangiomas present as red or purple raised patches that may blanch with pressure. Superficial lesions: bright red, compressible. Deep lesions: blue-purple nodules with skin-colored overlying skin. 60% occur on head/neck, 25% on trunk, 15% on extremities. Rapid growth typically occurs in first 3-6 months. Associated complications: ulceration (5-13%), bleeding, pain, impaired vision (periocular), or airway compromise.

Diagnosis

Clinical diagnosis reliable based on characteristic appearance, timing of onset, and growth pattern. Doppler ultrasound confirms diagnosis and assesses depth. MRI indicated for large facial lesions to rule out PHACES, periocular lesions threatening vision, or lesions near airway. Histology shows benign capillary endothelium proliferation with high mitotic activity. Immunohistochemistry for GLUT1 confirms diagnosis if uncertain.

Treatment (Age-Specific)

Infants (0-3 months): Observation appropriate for small, non-threatening lesions. However, early propranolol is indicated for high-risk locations or rapid growth. Propranolol dosing: 2-3 mg/kg/day divided 2-3 doses (maximum 160 mg/day). Initial low dose 0.5-1 mg/kg/day, increase gradually over 5-7 days. Requires baseline: HR, BP, ECG, echocardiogram for cardiac lesions.

Infants (3-12 months): Propranolol first-line for proliferating hemangiomas. Dosing: 2-3 mg/kg/day (often 1-2 mg/kg twice daily). 60-90% size reduction in 50% by 12 weeks. Duration: 6-12 months. Monitor: hypoglycemia (fasting), bradycardia, fatigue, bronchospasm.

Toddlers/Older Children (1-5 years): Propranolol continues effective for residual or new lesions. Dose adjusted by weight (maximum 160 mg/day). For refractory lesions: prednisolone 2-4 mg/kg/day divided once or twice daily (maximum 60-80 mg/day). Pulse corticosteroid therapy (IV methylprednisolone 30 mg/kg days 1-3 monthly) for severe cases.

Older Children (5+ years): Most hemangiomas involuting. Surgical excision of residual lesions after age 4-5. Pulsed dye laser (585-595 nm, 7-10 mm spot, 0.5-4 J/cm²) improves residual erythema. Surgical excision provides definitive treatment for therapy-refractory lesions.

Procedural details: Propranolol monitoring: baseline HR, BP, ECG, echo; repeat vitals 1-2 hours after dose increase; every 2-4 weeks during therapy. PDL: 585-595 nm wavelength, 7-10 mm spot, 0.5-1.5 J/cm² (purpura endpoint), 4-8 week intervals.

Prognosis

Approximately 90% of infantile hemangiomas undergo spontaneous involution by age 9 years. Propranolol therapy accelerates involution and prevents complications in 60-90%. However, 10-20% have residual lesions with permanent scarring or pigmentation changes. Early treatment of rapidly proliferating lesions significantly improves outcomes. Complications are preventable with appropriate management.

When to See a Pediatric Dermatologist

All presumed hemangiomas require specialist evaluation for confirmation and risk assessment. High-risk location lesions (periocular, perioral, anogenital), rapid growth, or ulceration require urgent referral. Large facial lesions need evaluation for PHACES with appropriate imaging. Specialists guide treatment decisions and monitor response.

FAQ

Q: Will my baby's hemangioma go away on its own?
A: Yes, 90% of infantile hemangiomas involute spontaneously by age 9. However, this can leave residual scarring or pigmentation. Early propranolol treatment prevents complications and improves final appearance. Your dermatologist advises whether observation or early treatment is best.

Q: Is propranolol safe for infants?
A: Propranolol is standard first-line treatment and safe when properly monitored. Dosing starts low and increases gradually. Regular monitoring includes heart rate, blood pressure, ECG, and echocardiogram. Main side effects are hypoglycemia (with fasting) and bronchospasm in children with reactive airway disease.

Q: Can hemangiomas cause serious problems?
A: Most are harmless and involute spontaneously. However, some cause complications: periocular lesions may impair vision, airway lesions may cause breathing problems, and other locations may cause disfigurement or bleeding. Early detection and treatment prevent these complications.

Q: What will the hemangioma look like after involution?
A: Hemangiomas may leave residual scarring, skin texture changes, or permanent pigmentation. Early propranolol treatment reduces these residual changes. Most show significant improvement by age 7-9 years, with minimal cosmetic impact for many children.

References

  1. Léauté-Labrèze C, Harper JI, Hoeger PH. Infantile haemangioma. Lancet. 2017;390(10089):85-94.
  2. Baum SH, Feins NR, Friedberg JL. Pediatric hemangiomas. Clin Dermatol. 2013;31(5):625-631.
  3. Drolet BA, Esterly NB, Frieden IJ. Hemangiomas in children. N Engl J Med. 1999;341(3):173-181.
  4. Metry D, Hebert AA. Hemangiomas and vascular tumors. Pediatr Clin North Am. 2006;53(2):375-384.
  5. Seid AM, Graffeo CS, Sorkina L, et al. PHACES syndrome. Curr Opin Otolaryngol Head Neck Surg. 2011;19(6):464-467.
  6. Enjolras O, Mulliken JB. Vascular tumors and malformations. Adv Dermatol. 1997;13:375-423.
  7. Léauté-Labrèze C, Dumas de la Roque E, Hubiche T, et al. Propranolol for severe hemangiomas. N Engl J Med. 2008;358(24):2649-2651.
  8. Bolton RA, Richards RN, Rumfo RP. Phototherapy in hemangiomas. J Cutan Med Surg. 2001;5(3):205-210.
  9. Buckmiller LM, Richter GT, Suen JY. Hemangiomas and vascular malformations. Otolaryngol Clin North Am. 2003;36(1):1-35.
  10. Marler JJ, Fishman SJ, Upton J, et al. Prenatal diagnosis of vascular anomalies. Semin Pediatr Surg. 2003;12(2):87-93.